
    
      This is a multi-center, randomized, double-blind, placebo-controlled study. A 3-stage
      adaptive design will be used. Following screening, eligible subjects will be randomized
      equally to 1 of 4 groups (ALKS33 [RDC-0313] [1, 2.5, OR 10 mg], or matching placebo).
    
  